-

$undefined

N/A

(N/A)

Apogee Therapeutics NasdaqGM:APGE Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Location: Building 17, Waltham, MA, 02453, United States | Website: https://www.apogeetherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.867B

Cash

513.3M

Avg Qtr Burn

-47.0M

Short % of Float

26.23%

Insider Ownership

7.63%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
APG777 Details
Atopic dermatitis

Big Mover™

Susp. Mover™

Phase 2

Data readout

Phase 2

Initiation

APG808 Details
Allergic diseases Type 2, Chronic obstructive pulmonary disease, Asthma

Phase 1b

Update

APG279 (APG777 + APG990) Details
Atopic Dermatitis (AD)

Phase 1b

Initiation

APG990 Details
Atopic dermatitis

Phase 1

Data readout

APG333 Details
Asthma, Chronic obstructive pulmonary disease

Phase 1

Data readout